Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF1) receptors: Identification of amino acids mediating high-affinity astressin binding and functional antagonism

Regulatory Peptides

Volumn 118, Issue 3, 2004, Pages 165-173

  Dautzenberg, Frank M ^a,c   Wille, Sandra ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Binding; CAMP; Ligand selectivity; Receptor mutagenesis

Indexed keywords

AMINO ACID; ARGININE; ASPARAGINE; ASTRESSIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GLUTAMIC ACID; GLUTAMINE; GLYCINE; PROTEIN SUBUNIT; TYROSINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; AMPHIBIA; ARTICLE; BINDING AFFINITY; BINDING SITE; CHIMERA; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; SITE DIRECTED MUTAGENESIS; XENOPUS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE; CELL MEMBRANE; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; EPITHELIAL CELLS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SHEEP; TRANSFECTION; XENOPUS;

AMPHIBIA;

EID: 1542300837     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2003.12.012     Document Type: Article

References (41)

1. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
2. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160:1999;1-12.
3. Smagin G.N., Dunn A.J. The role of CRF receptor subtypes in stress-induced behavioural responses. Eur. J. Pharmacol. 405:2000;199-206.
4. Dautzenberg F.M., Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 23:2002;71-77.
5. Hauger R.L., Grigoriadis D.E., Dallman M.F., Plotsky P.M., Vale W.W., Dautzenberg F.M. International Union of Pharmacology: XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev. 55:2003;21-26.
6. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S.et al. Urocortin, a mamalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (London). 378:1995;287-292.
7. Donaldson C., Sutton S., Perrin M.H., Corrigan A.Z., Lewis K.A., Rivier J.et al. Cloning and characterization of human urocortin. Endocrinology. 137:1996;2167-2170.
8. Lederis K., Letter A., McMaster D., Moore G. Complete amino acid sequence of urotensin-I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. Science. 218:1982;162-165.
9. Montecucchi P.C., Henschen A. Amino acid composition and sequence analysis of sauvagine, a new active peptide from the skin of Phyllomedusa sauvagei. Int. J. Pept. Protein Res. 18:1981;113-120.
10. Hsu S.Y., Hsueh A.J.W. Human stresscopin and stresscopin-related peptide are selective ligands for the corticotropin-releasing hormone receptor. Nat. Med. 7:2001;605-611.
11. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C.et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U. S. A. 98:2001;7570-7575.
12. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A.et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U. S. A. 98:2001;2843-2848.
13. Dautzenberg F.M., Kilpatrick G.J., Hauger R.L., Moreau J.-L. Molecular biology of the CRH receptors - in the mood. Peptides. 22:2001;753-760.
14. Hauger R.L., Dautzenberg F.M. Regulation of the stress response by corticotropin-releasing factor receptors. Conn P.M., Freedman M.E. Neuroendocrinology in Physiology and Medicine. 1999;261-286 Humana Press, Totowa.
15. Kilpatrick G.J., Dautzenberg F.M., Martin G.R., Eglen R.M. G-protein coupled receptors - the splicing on the cake. Trends Pharmacol. Sci. 20:1999;294-301.
16. Arai M., Assil I.Q., Abou-Samra A.B. Characterization of three corticotropin-releasing factor receptors in catfish: a novel third receptor is predominantly expressed in pituitary and urophysis. Endocrinology. 142:2001;446-454.
17. Dautzenberg F.M., Dietrich K., Palchaudhuri M.R., Spiess J. Identification of two corticotropin-releasing factor receptors with high ligand selectivity from Xenopus laevis: unusual pharmacology of the type 1 receptor. J. Neurochem. 69:1997;1640-1649.
18. Dautzenberg F.M., Kilpatrick G.J., Wille S., Hauger R.L. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptors reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile. J. Neurochem. 73:1999;821-829.
19. Palchaudhuri M.R., Wille S., Mevenkamp G., Spiess J., Fuchs E., Dautzenberg F.M. Corticotropin-releasing factor receptor type 1 from Tupaia belangeri: cloning, functional expression and tissue distribution. Eur. J. Biochem. 258:1998;78-84.
20. Dautzenberg F.M., Py-Lang G., Higelin J., Fischer C., Wright M.B., Huber G. Different binding modes of amphibian and human CRF type 1 and type 2 receptors: evidence for evolutionary differences. J. Pharmacol. Exp. Ther. 296:2001;113-120.
21. 3H]-urocortin. Neuropharmacology. 36:1997;1439-1446.
22. 2 α and β splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. Neuropharmacology. 38:1999;441-448.
23. Palchaudhuri M.R., Hauger R.L., Wille S., Fuchs E., Dautzenberg F.M. Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangeri. J. Neuroendocrinol. 11:1999;419-428.
24. 2 receptor mediate differential binding of CRF ligands in comparison to its human counterpart. Mol. Pharmacol. 61:2002;1132-1139.
25. Dautzenberg F.M., Wille S., Lohmann R., Spiess J. Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4941-4946.
26. Wille S., Sydow S., Palchaudhuri M.R., Spiess J., Dautzenberg F.M. Identification of amino acids in the N-terminal domain of corticotropin- releasing factor receptor 1 that are important determinants of high affinity ligand binding. J. Neurochem. 72:1999;388-395.
27. Hauger R.L., Dautzenberg F.M., Flaccus A., Liepold T., Spiess J. Regulation of corticotropin-releasing factor receptor function in human Y-79 retinoblastoma cells: rapid and reversible homologous desensitization but prolonged recovery. J. Neurochem. 68:1997;2308-2316.
28. 2α receptors and the role of position 185 for receptor-ligand selectivity. Neuropharmacology. 39:2000;1368-1376.
29. Eckart K., Jahn O., Radulowic J., Tezval H., van Werven L., Spiess J. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11142-11147.
30. Perrin M.H., Sutton S.W., Cervini L.A., Rivier J.E., Vale W.W. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J. Pharmacol. Exp. Ther. 288:1999;729-734.
31. Rühmann A., Bonk I., Lin C.R., Rosenfeld M.G., Spiess J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2β-selective antisauvagine-30. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15264-15269.
32. Gulyas J., Rivier C., Perrin M., Koerber C., Sutton S., Corrigan A.et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc. Natl. Acad. Sci. U. S. A. 92:1995;10575-10579.
33. Hoare S.R., Sullivan S.K., Ling N., Crowe P.D., Grigoriadis D.E. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol. Pharmacol. 63:2003;751-765.
34. Perrin M.H., Sutton S., Bain D., Berggren W.T., Vale W.W. The first extracellular domain of corticotropin-releasing factor-R1 contains major binding determinants for urocortin and astressin. Endocrinology. 139:1998;566-570.
35. Perrin M.H., Fischer W.H., Kunitake K.S., Craig A.G., Koerber S.C., Cervini L.A.et al. Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor. J. Biol. Chem. 276:2001;31528-31534.
36. Nielsen S.M., Nielsen L.Z., Hjorth S.A., Perrin M.H., Vale W.W. Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10277-10281.
37. Assil I.Q., Qi L.J., Arai M., Shomali M., Abou-Samra A.B. Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction. Biochemistry. 40:2001;1187-1195.
38. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8967-8971.
39. Vita N., Laurent P., Lefort S., Chalon P., Lelias J.M., Kaghad M.et al. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett. 335:1993;1-5.
40. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54:2002;323-374.
41. Sabroe I., Peck M.J., Van Keulen B.J., Jorritsma A., Simmons G., Clapham P.R.et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3: potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. 275:2000;25985-25992.